{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+comparison&page=10", "query": { "intervention": "Control comparison", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 4175, "total_pages": 418, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+comparison&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+comparison&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T06:18:26.708Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05814627", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib Matching Placebo", "type": "DRUG" }, { "name": "Adalimumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2023-06-15", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 85, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814627" }, { "nct_id": "NCT00224120", "title": "A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Benign Prostatic Hyperplasia" ], "interventions": [ { "name": "Silodosin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Watson Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "MALE", "summary": "50 Years and older · Male only" }, "enrollment_count": 462, "start_date": "2005-05", "completion_date": "2006-05", "has_results": true, "last_update_posted_date": "2009-12-15", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Carmichael, California • Fresno, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Carmichael", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Laguna Woods", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224120" }, { "nct_id": "NCT00012324", "title": "Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "nolatrexed dihydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eximias Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-09", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 38, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012324" }, { "nct_id": "NCT01974323", "title": "Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Dapsone Gel", "type": "DRUG" }, { "name": "Dapsone Gel Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Almirall, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 2238, "start_date": "2013-11", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 2, "location_summary": "Beverly Hills, California • Aventura, Florida", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01974323" }, { "nct_id": "NCT04677959", "title": "A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone propionate/salmeterol (FS)", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" }, { "name": "Standard of Care Asthma Medication", "type": "DRUG" }, { "name": "Standard of Care Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 427, "start_date": "2021-02-16", "completion_date": "2022-03-10", "has_results": true, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04677959" }, { "nct_id": "NCT00201981", "title": "A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Keratoconjunctivitis Sicca" ], "interventions": [ { "name": "Rebamipide 1%", "type": "DRUG" }, { "name": "Rebamipide 2%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 755, "start_date": "2004-05-01", "completion_date": "2007-02-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201981" }, { "nct_id": "NCT04446312", "title": "Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colonoscopy" ], "interventions": [ { "name": "Bowel Prep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Braintree Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 500, "start_date": "2020-07-13", "completion_date": "2021-02-05", "has_results": true, "last_update_posted_date": "2023-10-27", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 34, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04446312" }, { "nct_id": "NCT06030531", "title": "Spasticity and Functional Recovery After SCI", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Spinal Cord Injury", "Spinal Cord Injuries" ], "interventions": [ { "name": "Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation", "type": "OTHER" }, { "name": "Analysis of biomarkers", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Shirley Ryan AbilityLab", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2020-07-01", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06030531" }, { "nct_id": "NCT05109702", "title": "A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dry Eye" ], "interventions": [ { "name": "0.25% Tanfanercept Ophthalmic Solution", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HanAll BioPharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2021-11-18", "completion_date": "2022-05-06", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Raynham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05109702" }, { "nct_id": "NCT00138645", "title": "The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Body Weight Changes" ], "interventions": [ { "name": "MicroDiet", "type": "BEHAVIORAL" }, { "name": "Healthy Diet", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Pennington Biomedical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2005-04", "completion_date": "2006-05", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-11-15T06:18:26.708Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00138645" } ] }